Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Cell Therapy grants Daiichi Sankyo Japan license for its heart regeneration therapy

May 10, 2016

Chiesi Farmaceutici to acquire The Medicines Co.'s non-core cardiovascular assets

May 10, 2016

Ischemix's phase II CARIN trial misses prespecified endpoints

May 4, 2016

MYK-461 granted FDA orphan status for symptomatic obstructive hypertrophic cardiomyopathy

May 4, 2016

Merck & Co. patents PAR1 receptor antagonists

May 2, 2016

Abbott set to acquire St. Jude Medical

April 29, 2016

First patient randomized in the dalGenE phase III cardiovascular outcomes trial

April 28, 2016

Merck & Co. discloses ROMK blockers

April 28, 2016

F. Hoffmann-La Roche patent divulges CYP11B2 inhibitors

April 26, 2016

FDA accepts NanoCor's IND for Carfostin

April 25, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.